GSK forges $12 billion alliance with Hengrui Pharma
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Revenue increased 11.4 per cent to Rs. 8,545 crore
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Subscribe To Our Newsletter & Stay Updated